Sorafenib

Generic Name
Sorafenib
Brand Names
Nexavar, Sorafenib Accord
Drug Type
Small Molecule
Chemical Formula
C21H16ClF3N4O3
CAS Number
284461-73-0
Unique Ingredient Identifier
9ZOQ3TZI87
Background

Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...

Indication

Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.

Associated Conditions
Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
Associated Therapies
-
Clinical Trials
Related News

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

First Posted Date
2018-08-14
Last Posted Date
2021-07-14
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
6
Registration Number
NCT03630120
Locations
๐Ÿ‡บ๐Ÿ‡ธ

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)

First Posted Date
2018-07-31
Last Posted Date
2024-11-14
Lead Sponsor
NovoCure Ltd.
Target Recruit Count
25
Registration Number
NCT03606590
Locations
๐Ÿ‡จ๐Ÿ‡ฟ

University Hospital Fakultni Nemocnice Olomouc, Oncology Clinic, Olomouc, Czechia

๐Ÿ‡ฉ๐Ÿ‡ช

Ulm University Hospital, Ulm, Germany

๐Ÿ‡ซ๐Ÿ‡ท

CHU de Nantes, Nantes Cedex 01, France

and more 5 locations

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

First Posted Date
2018-07-11
Last Posted Date
2023-01-10
Lead Sponsor
TaiRx, Inc.
Target Recruit Count
12
Registration Number
NCT03582618
Locations
๐Ÿ‡จ๐Ÿ‡ณ

National Taiwan University Hospital, Taipei, Taiwan

๐Ÿ‡จ๐Ÿ‡ณ

National Cheng Kung University Hospital, Tainan, Taiwan

๐Ÿ‡บ๐Ÿ‡ธ

Charleston Hematology Oncology Associates, Charleston, South Carolina, United States

SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC

First Posted Date
2018-07-06
Last Posted Date
2020-04-09
Lead Sponsor
The University of Hong Kong
Target Recruit Count
15
Registration Number
NCT03578874
Locations
๐Ÿ‡ญ๐Ÿ‡ฐ

Queen Mary Hospital, Hong Kong, Hong Kong

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

First Posted Date
2018-06-20
Last Posted Date
2021-03-18
Lead Sponsor
ImmunityBio, Inc.
Registration Number
NCT03563170
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

First Posted Date
2018-05-23
Last Posted Date
2024-12-05
Lead Sponsor
Children's Oncology Group
Target Recruit Count
537
Registration Number
NCT03533582
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

๐Ÿ‡บ๐Ÿ‡ธ

Children's Hospital of Alabama, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 202 locations

Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis

First Posted Date
2018-05-08
Last Posted Date
2018-05-08
Lead Sponsor
Korea University
Target Recruit Count
130
Registration Number
NCT03518502
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

Seoul Saint Marry Hospital, the Catholic University of Korea, Seoul, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

Chonnam National University Hwasoon Hospital, Gwangju, Korea, Republic of

and more 3 locations

HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC

First Posted Date
2018-03-16
Last Posted Date
2018-03-16
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
300
Registration Number
NCT03468231
Locations
๐Ÿ‡จ๐Ÿ‡ณ

Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

๐Ÿ‡จ๐Ÿ‡ณ

First Affiliated Hospital of University Of South China, Hengyang, Hunan, China

๐Ÿ‡จ๐Ÿ‡ณ

Dongguan People's Hospital, Dongguan, Guangdong, China

and more 4 locations

Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

First Posted Date
2018-02-20
Last Posted Date
2024-02-21
Lead Sponsor
Robin Kate Kelley
Target Recruit Count
16
Registration Number
NCT03439891
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of California, Davis, Sacramento, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of California, San Francisco, San Francisco, California, United States

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

First Posted Date
2018-02-15
Last Posted Date
2023-10-23
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
558
Registration Number
NCT03434379
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Hokkaido University Hospital, Hokkaido, Japan

๐Ÿ‡ฉ๐Ÿ‡ช

Campus Virchow-Klinikum Charitรฉ Centrum 13; Medizinische Klinik; Abt.Hepatologie u.Gastroenterologie, Berlin, Germany

๐Ÿ‡จ๐Ÿ‡ฆ

Jewish General Hospital, Montreal, Quebec, Canada

and more 116 locations
ยฉ Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy